Get started
Aptevo Therapeutics Inc.Aptevo Therapeutics Inc.Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

APVO trade ideas

Compelling Long TradeGreetings, fellow traders! Today, I am thrilled to present an exciting and potentially lucrative long trade opportunity that combines various compelling factors. This trade idea is backed by the convergence of three drives lower, favorable fundamentals, three consecutive days of lower prices, and the recent absorption of sellside liquidity. With careful analysis and attention to risk management, we aim to enter the market at $1.58 , place a stop loss at $1.49 , and set an ambitious target of $2.91 . Along the way, we will consider taking partial profits at key levels, including $2.10, $2.24, and $2.58, ultimately maximizing our potential gains. The remarkable risk-reward ratio of approximately 1 to 19.29 further enhances the appeal of this trade. Let's delve into the details and explore each factor that strengthens our conviction in this trade. Firstly, the presence of three drives lower indicates a potential exhaustion of selling pressure and signals a potential reversal in the price action. Combined with favorable fundamentals, this trade idea aligns with the broader market context, increasing the likelihood of a successful outcome. Furthermore, the consecutive lower days provide evidence of a downward trend losing momentum, setting the stage for a potential upward reversal. Additionally, the absorption of sellside liquidity serves as a critical turning point in the market dynamics. As the selling is neutralized, it opens up the possibility of increased buying interest and potential price appreciation. This favorable shift in liquidity dynamics further bolsters our case for a long trade. To effectively manage risk, we will set a stop loss at $1.49. This level provides a buffer below our entry point, helping to mitigate potential losses in the event of adverse price movements. It is crucial to adhere to this risk management strategy to safeguard our capital and preserve our trading account. As we progress in the trade, we will consider taking partial profits at strategic levels. Partial take profits at $2.10, $2.24, and $2.58 will allow us to lock in gains along the way and potentially capitalize on price retracements. This approach enables us to realize profits while still allowing for potential upside continuation. Moreover, the impressive risk-reward ratio of approximately 1 to 19.29 showcases the asymmetric nature of this trade opportunity. By carefully managing our risk and aiming for substantial rewards, we position ourselves for significant profit potential relative to the risk involved. Lastly, we will keep a watchful eye on the weekly bearish order block as a potential exit point. This level on the higher timeframe could act as a significant resistance area, potentially affecting price dynamics and signaling a prudent time to close the trade. Remember, successful trading requires discipline, patience, and continuous monitoring of the trade's progress. Market conditions can change, and it is crucial to remain adaptable and adjust our approach accordingly. To enhance the presentation of my trading idea, I'm providing chart example with detailed markup. Visual aids make it easier for you to understand the trade setup, key levels, and anticipated price movements, ultimately making your idea more engaging and insightful. With over 50 million active users on TradingView, it can be challenging to stand out. However, if you could help me and give the boost to this idea I would appreciate it! Thank you! Please keep in mind that trading involves risks, and this trade idea is shared for educational purposes only. It is essential to conduct your own analysis, consider your risk tolerance, and, if needed, seek advice from qualified professionals before making any trading decisions. TRADING as a BUSINESS wishing you success and profitable trades!
NASDAQ:APVOLong
by unfair_advantage
$APVOAptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
NASDAQ:APVOLong
by BADQOMOCAWGOWLD
1
$APVO Nov. 05th 2020 Long day trading Opportunitywait for a pullback and consolidation with $APVO $14.42 to $14.5 Entry point for APVO SL $13.99 1st Take Profit point 50% holding at $18 2nd Take Profit point at $23.90 (3rd Squeeze, or the last potential squeeze) if APVO $14 not violated and Consolidate above vwap if the 3rd breakout at $19.46 occur with APVO, we could see another 23-24% Upside Squeeze from the $19.46 breakout point 1st squeeze had a 23% upside from 9.15 2nd squeeze had a 23% upside from 11.65 3rd squeeze will have another 23% upside from the 19.42 Breakout PS: tomorrow 10:40 AM and beyond APVO has to hold above $16.28 for any hope of $19.32 breakout key level $16.5 for hope of 19.32 breakout and if $14 get violated downwards might signal an authentic backside
NASDAQ:APVOLong
by danzb2020
4
receive Seven Year Quarterly Royalty Payment Stream from Pfizer Aptevo Therapeutics to receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimilar. it will receive a royalty from Pfizer related to sales of a rituximab biosimilar product, RUXIENCE® (Rituximab-pvvr), which was approved by the U.S. Food and Drug Administration in July 2019 and launched by Pfizer in the United States and Japan in early 2020. This funding will help to support the advancement of our novel ADAPTIR™ bispecific antibody platform and more specifically, our lead ADAPTIR bispecific candidate, APVO436, which is progressing in a Phase 1/1b clinical study for the treatment of acute myeloid leukemia. Dosing in cohort 6 of the study is currently underway. We look forward to providing an update on this clinical program as additional data are available." Published Articles Suggest the Global Market for Rituximab Biosimilars Could Potentially be over $1 Billion Per Year Royalty Stream Relates to Agreement Acquired in Aptevo Spin-off from Emergent BioSolutions
NASDAQ:APVO
by AlenCiken
APVO Breakout Imminent? Fib Retrace + Res Lin CrossingAPVO is a funny stock in that it rocketed past $4 and subsequently fell just as hard and fast. The fall was never really explained as far as I know. SEC filings have come up fairly recently and are positive. Median resistance line shows an incubation level that's held. Previous breakout was right up against it. Current levels are holding above it and about to test next Fib level. Biotech is always an interesting play and APVO has a great timeline for 2018 and its products and test results. Overall market stability will hopefully start to take seed with a new month starting next week that could help APVO momentum. Expecting some $4 levels again in the near future.
NASDAQ:APVO
by N3utra